Section on Translational Tumor Immunology, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Building 10, Room 7N240C, Bethesda, MD 20892, USA.
Otolaryngol Clin North Am. 2021 Aug;54(4):769-777. doi: 10.1016/j.otc.2021.05.002. Epub 2021 Jun 5.
This article aims to educate readers on adjuvant therapies for recurrent respiratory papillomatosis (RRP). Although antivirals are injected locally into papillomas as an adjuvant treatment, new biologics targeting vascular endothelial growth factor or induction of human papillomavirus (HPV)-specific immunity are gaining traction with demonstration of clinical benefit and mechanism of action in retrospective case series and prospective clinical trials. The future of RRP treatment, alone or in combination with surgery, lies in the careful clinical study of vascular and immune targeting agents that balance the risk of adverse events with the chance for elimination of HPV-infected cells.
本文旨在为读者介绍复发性呼吸道乳头瘤病（RRP）的辅助治疗方法。虽然抗病毒药物被局部注射到乳头瘤中作为辅助治疗，但针对血管内皮生长因子或诱导 HPV 特异性免疫的新型生物制剂在回顾性病例系列和前瞻性临床试验中显示出临床获益和作用机制，越来越受到关注。RRP 的治疗方法，无论是单独使用还是与手术结合使用，未来都在于仔细研究血管和免疫靶向药物，在平衡不良反应风险与消除 HPV 感染细胞的机会之间取得平衡。
